Dare Bioscience
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period study enrollment expected to complete in with approximately subjects topline data of phase respond study targeted for | Dare Bioscience
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
34 of 50
Similar slides by Dare Bioscience
See diffirences between slides (animation)
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Related slides by other companies
Nuvalent
Investor Presentation
February 2024
the path to patient impact program status first approved a toe pivotal data naive and study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in for her | Nuvalent
Nuvalent
Investor Presentation
April 2024
lated cone program status pivotal data naive and first approved product study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in i he | Nuvalent
RenovoRx
IPO
August 2021
designed for success one phase trial to approval pivotal tiger pac phase study schema currently enrolling | RenovoRx
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Other recent decks by Dare Bioscience
See all presentations (5 decks)
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
July 2023
Investor Presentation
February 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights